Postmarket Study to Evaluate Biovance® in Diabetic Foot Ulcers

NAUnknownINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

December 31, 2017

Conditions
Diabetic Foot Ulcers
Interventions
OTHER

Biovance®

Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading

OTHER

Standard of Care, Diabetic Foot Ulcers

Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner

Trial Locations (10)

10025

St. Luke's Roosevelt Hospital Center, New York

18015

Foot and Ankle Center at Coordinated Health, Bethlehem

20057

Georgetown University, Washington D.C.

32216

First Coast Cardiovascular Institute, Jacksonville

36111

Institute of Advanced Wound Healing, Montgomery

38103

University of Tennessee Health Sciences Center, Memphis

85253

Banner Health, Phoenix

90057

Foot and Ankle Clinic, Los Angeles

90822

Southern California Institute for Research and Education (VA), Long Beach

93721

Limb Preservation Platform, Fresno

Sponsors
All Listed Sponsors
lead

Alliqua BioMedical, Inc

INDUSTRY

NCT02506452 - Postmarket Study to Evaluate Biovance® in Diabetic Foot Ulcers | Biotech Hunter | Biotech Hunter